Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering
MWN-AI** Summary
Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) recently announced the final results of its $25 million rights offering, which closed on May 29, 2025. The offering attracted subscriptions for 3,130,480 shares of Class B common stock at an exercise price of $1.28 per share, resulting in gross proceeds of approximately $4 million. Notably, Howard Jonas, the company’s CEO, and his affiliates, who own about 32% of Rafael’s common stock, opted not to exercise their subscription rights as they previously committed to backstop the offering. This means they will purchase any unsubscribed shares, totaling approximately $21 million.
The subscribed shares were distributed to participating shareholders on June 4, 2025. Jonas expressed gratitude towards the stockholders for their participation and highlighted that the proceeds will help fund regulatory approval efforts and potentially launch Trappsol® Cyclo™, pending positive interim results from a critical Phase 3 clinical trial for Niemann-Pick Disease Type C1 (NPC1).
Following the completion of both the rights offering and the anticipated backstop private placement, Rafael expects to have about 50,879,164 shares of Class B and 787,163 shares of Class A common stock outstanding, with additional proceeds estimated at $24.9 million post-expenses.
Rafael Holdings focuses on clinical and early-stage pharmaceutical developments, notably through its subsidiary Cyclo Therapeutics, and holds stakes in several biotech and pharmaceutical companies. The company filed the rights offering registration statement with the SEC, making related documents accessible to potential investors. Cautionary statements regarding forward-looking projections were also made, stressing the inherent risks and uncertainties associated with drug development and market performance.
MWN-AI** Analysis
Rafael Holdings, Inc. (NYSE: RFL) has recently concluded a rights offering aimed at raising $25 million, yet it garnered only around $4 million in subscriptions from other shareholders, with the majority of the required funding being backstopped by CEO Howard Jonas and affiliates. This move is strategic, particularly as Rafael prepares for significant clinical trials concerning its lead drug candidate, Trappsol® Cyclo™, which is under evaluation for the treatment of Niemann-Pick Disease Type C1 (NPC1).
Investors must reflect on several factors following this announcement. Firstly, the lower-than-expected subscription response from existing shareholders could indicate market apprehension regarding the company’s future prospects or skepticism about the viability of its pipeline. The successful backstop by Mr. Jonas, while providing immediate funding stability, raises questions about the robustness of retail investor confidence in the stock.
The rights offering proceeds, alongside the impending completion of the backstop, will bolster Rafael’s balance sheet, crucial as it continues the regulatory approval efforts for Trappsol® Cyclo™. The Phase 3 trial results will be pivotal and could dramatically influence stock performance. Investors should closely monitor these results, as a favorable outcome could lead to significant appreciation in share value.
Furthermore, the diversification in Rafael's portfolio, which includes various clinical and early-stage pharmaceutical companies, might present a hedge against risks associated with NPC1. Investors contemplating entry into Rafael must consider the speculative nature of biotech investments, particularly with early-stage companies facing a high rate of failure.
In conclusion, while Rafael Holdings presents a potential growth opportunity, particularly with upcoming clinical data, the cautious approach from the market and the reliance on backstop funding signal that investors should remain vigilant and informed about both the company’s developments and broader sector trends. Patience and careful monitoring could yield rewards, depending on the pivotal Phase 3 trial outcomes.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEWARK, N.J., June 04, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) announced today the final results and closing of its $25.0 million rights offering (the “Rights Offering”). The subscription period of the Rights Offering expired at 5:00 P.M. Eastern Time, on May 29, 2025. The Rights Offering resulted in subscriptions for 3,130,480 shares of Class B common stock at an exercise price of $1.28 per share for aggregate gross proceeds of $4,007,014.40.The subscriptions do not reflect subscription rights held by Howard Jonas, Chief Executive Officer, President and Executive Chairman of the Company and Chairman of the Board of Directors of the Company, and his affiliates who held, prior to the rights offering, approximately 32% of the outstanding common stock of the Company. Due to Mr. Jonas’ previously disclosed commitment to backstop the Rights Offering through a private placement of shares in the event that the Rights Offering was not fully subscribed (the “Backstop Private Placement”), those holders did not exercise their subscription rights. Mr. Jonas and certain related parties are purchasing the unsubscribed shares for an aggregate amount of $20,992,985.60.
The shares of Class B common stock subscribed for by stockholders were issued to participating stockholders on June 4, 2025.
Mr. Jonas commented, “I want to thank all of the stockholders that participated in the Rights Offering. The proceeds from the Rights Offering will provide the Company additional capital for the regulatory approval efforts and potential launch of Trappsol ® Cyclo™ in the event of a positive interim result from the 48-week interim analysis of the TransportNPC™ Phase 3 clinical trial in Niemann-Pick Disease Type C1 (“NPC1”).
The Backstop Private Placement is expected to be completed within the next several business days.
The net proceeds to be received by the Company in the Rights Offering and the Backstop Private Placement are expected to be approximately $24.9 million after deduction of certain expenses incurred by the Company in connection with the Rights Offering.
Following the completion of the Rights Offering and the Backstop Private Placement, the Company expects to have approximately 50,879,164 shares of its Class B common stock and 787,163 shares of its Class A common stock (which are convertible into Class B common stock on a one for one basis) outstanding.
A registration statement on Form S-3 (File No. 333-286622) relating to the Rights Offering was filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”). The Rights Offering was made only by means of a prospectus, copies of which can be accessed through the SEC’s website at www.sec.gov. Additional information regarding the Rights Offering is set forth in the prospectus filed with the SEC.
About Rafael Holdings, Inc.
Rafael Holdings, Inc. holds interests in clinical and early-stage pharmaceutical and certain other companies, including our wholly-owned subsidiary, Cyclo Therapeutics, LLC, a clinical stage biotechnology company dedicated to developing Rafael’s lead clinical candidate, Trappsol ® Cyclo™, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 (“NPC1”), a rare, fatal, and progressive genetic disorder. Rafael also holds majority equity interests in LipoMedix Pharmaceuticals Ltd., a clinical stage pharmaceutical company, Cornerstone Pharmaceuticals, Inc., formerly known as Rafael Pharmaceuticals Inc., a cancer metabolism-based therapeutics company, Rafael Medical Devices, LLC, an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries, and Day Three Labs, Inc., a company which empowers third-party manufacturers to reimagine their existing cannabis offerings.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; plans regarding the further evaluation of clinical data; and the potential of our pipeline, including our internal cancer metabolism research programs. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, those disclosed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended July 31, 2024, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
Investor Contact:
Rafael Holdings, Inc.
Barbara Ryan
Barbara.ryan@rafaelholdings.com
(203) 274-2825
FAQ**
How will the $25 million rights offering impact Rafael Holdings Inc. Class B RFL's financial stability and its ability to fund the regulatory approval efforts for Trappsol® Cyclo™?
Given the significant backing from CEO Howard Jonas, what does the participation in Rafael Holdings Inc. Class B RFL rights offering indicate about his confidence in the company’s future prospects?
What are the anticipated outcomes of the upcoming interim analysis of the TransportNPC™ Phase 3 clinical trial for Rafael Holdings Inc. Class B RFL, and how could these results affect investor sentiment?
Can you elaborate on the strategic plans for the proceeds from Rafael Holdings Inc. Class B RFL’s rights offering and backstop private placement in relation to its product pipeline development?
**MWN-AI FAQ is based on asking OpenAI questions about Rafael Holdings Inc. Class B (NYSE: RFL).
NASDAQ: RFL
RFL Trading
2.74% G/L:
$1.50 Last:
103,086 Volume:
$1.57 Open:
